Leukemia/Myelodysplastic Syndrome
- AALL0232 High Risk B-Precursor Acute Lymphoblastic Leukemia
- AALL0331 Standard Risk B-Precursor Acute Lymphoblastic Leukemia
- AALL03B1 Classification of Acute Lymphoblastic Leukemia
- AALL03N1 Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia
- AALL0434 Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL)
- AALL05B1 A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
- AALL06N1 A Study of Neurocognitive Function in Children Treated for Acute Lymphoblastic Leukemia ( ALL)
- AALL0622 Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969, NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- AALL07P1 A Phase II Pilot Trial of Bortezomib (PS-341, Velcade, IND# 58,443 ) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
- AALL07P2 Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase®; Crisantaspase; IND 290) Following Allergy to PEG-Asparaginase in Treatment of Children with Acute Lymphoblastic Leukemia (ALL)
- AALL07P4 A Pilot Study of Intravenous EZN-2285 (SC-PEG E. coli L-asparaginase, IND# 100594) or Intravenous Oncaspar in the Treatment of Patients with High-Risk Acute Lymphoblastic Leukemia (ALL)
- AAML0523 A Phase I/II Study of CLOLAR (Clofarabine IND# 73,789) in Combination with Cytarabine in Pediatric Patients with Refractory/Relapsed Leukemia
- AAML0531 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
- AAML06P1 A Pilot Study of Lestaurtinib (CEP-701) in Combination with Chemotherapy in Young Patients with Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia
- AAML07P1 A Phase II Pilot Study of Bortezomib (PS-341, Velcade, IND #58,443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia
- ADVL04P2 A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relasped CD-22 Positive Acute Lymphoblastic Leukemia (ALL)
Solid Tumors
- 9346 Hepatoblastoma Biology Study and Tissue Bank
- 9902 A Group-wide Protocol for Collecting & Banking Pediatric Cancer Research Specimens: An Inter-group Rhabdomyosarcoma Study Group Protocol
- ABTR01B1 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
- ADVL0221 A Phase II Study of Trabectedin (ET-743, Yondelis® ) in Children with Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Non-rhabdomyosarcomatous Soft Tissue Sarcomas
- ADVL0525 A Phase II Study of Pemtrexed in Children with Recurrent Malignancies
- ADVL0821 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, IND# 100947, NSC# 742460) in Children With Relapsed/Refractory Solid Tumors
- AEPI04C1 Low Birth Weight and Other Risk Factors for Hepatoblastoma
- AEWS0331 European Ewing Tumor Working Initiative of National Groups Ewing Tumor Studies 1999 (EURO-E.W.I.N.G.99)
- AEWS07B1 A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens
- AEWS07P1 A Pilot Study of Chemotherapy Intensification by adding Vincristine, Topotecan and Cyclophosphamide to Standard Chemotherapy Agents with an Interval Compression Schedule in Newly Diagnosed Patients with Localized Ewing Sarcoma Family of Tumors
- AGCT0132 A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors
- AHOD0031 A Phase III Groupwide study of Dose-Intensive Response-based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease
- AHOD03P1 Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)
- ANBL00B1 Neuroblastoma Biology Study
- ANBL0032 Phase III Randomized Study of Chimeric Anti-GD2 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
- ANBL0531 Response- and Biology-based Therapy for Intermediate-risk Neuroblastoma
- ANBL0532 Phase III Randomized Trial of Single vs. Tandem Myeloablative as Consolidation Therapy for High-Risk Neuroblastoma
- ANBL0621 A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children with Relapsed or Refractory Neuroblastoma
- ANHL04B1 Rare and Cutaneous Non-Hodgkin's Lymphoma Registry
- AOST0331 A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy
- AOST06B1 A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
- AOST06P1 Feasibility and Dose Discovery Analysis of Zoledronic Acid with Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma
- ARAR0331 Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy
- AREN0321 Treatment of High Risk Renal Tumors
- AREN03B2 Renal Tumors Classification, Biology, and Banking Study
- AREN0532 Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
- AREN0533 Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
- ARET0332 A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy
- ARST0331 Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
- ARST0332 Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas NRSTS
- ARST0531 Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
Other
- ABTR01B1 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
- ABTR06C1 Pharmacokinetics of Daunomycin in Children
- ACCL05C1 A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy
- ACCRN07 Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
- ADVL06B1 A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer
- ADVL08N1 A Pharmacokinetic Participation Questionnaire Study
- ALTE03N1 Key Adverse Events after Childhood Cancer
- ALTE05N1 Umbrella Long-term Follow-up Protocol
- 06-0097 Documenting Speech and Language Impairment in Pediatric Oncology Patients with Sensorineural Hearing Loss
Brain Tumors/CNS Tumors
- ACNS02B1 Pre-clinical Pharmacology in Surgical Brain Tumor Specimens
- ACNS02B3 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
- ACNS0221 A Phase II Study of Conformal Radiotherapy in Patients with Low Grade Gliomas
- ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
- ACNS0332 Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
- ACNS0333 Treatment of Atypical Teratoid/Rhabdoid Tumors of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation
- ACNS0334 A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate
- ACNS0621 Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma
- ADVL0525 A Phase II Study of Pemtrexed in Children with Recurrent Malignancies
- 09-0569 HEAD START III Dose Intensive Chemotherapy For Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed By Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue
Phase I Protocols
- ADVL0413 A Phase I Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in Children with Refractory Solid Tumors or Refractory Leukemias
- ADVL0612 A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors
- ADVL0714 A Phase I Trial of VEGF Trap (NSC# 724770, IND# 100137) in Children with Refractory Solid Tumors
- ADVL0812 A Phase I Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children with Relapsed/Refractory Solid Tumors and Leukemia
- ADVL0813 A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor–I Receptor Monoclonal Antibody) in Combination with CCI-779 (Temsirolimus) in Pediatric Patients with Recurrent or Refractory Solid Tumors
- ADVL0816 A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination with Vincristine/Doxorubicin/Dexrazoxane, in Children with Relapsed/Refractory Solid Tumors or Leukemia
- 08-0773 A Phase I Trial of Arsenic Trioxide in the Treatment of Infiltrating Gliomas of Childhood